

# Nathalie Gaspar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3270707/publications.pdf>

Version: 2024-02-01

36  
papers

1,528  
citations

516710

16  
h-index

315739

38  
g-index

40  
all docs

40  
docs citations

40  
times ranked

2227  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. <i>Journal of Clinical Oncology</i> , 2015, 33, 3036-3046.	1.6	516
2	Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 446-455.	10.7	182
3	Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial. <i>Clinical Cancer Research</i> , 2017, 23, 6101-6112.	7.0	102
4	Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study. <i>European Journal of Cancer</i> , 2018, 88, 57-66.	2.8	74
5	Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group. <i>European Journal of Cancer</i> , 2016, 61, 128-136.	2.8	69
6	Phase-II trials in osteosarcoma recurrences: A systematic review of past experience. <i>European Journal of Cancer</i> , 2017, 75, 98-108.	2.8	58
7	Risk adapted chemotherapy for localised Ewing's sarcoma of bone: The French EW93 study. <i>European Journal of Cancer</i> , 2012, 48, 1376-1385.	2.8	53
8	Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility. <i>Nature Communications</i> , 2018, 9, 3184.	12.8	50
9	Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1312-1321.	10.7	50
10	A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1541-1549.	2.0	31
11	Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)†. <i>ESMO Open</i> , 2021, 6, 100250.	4.5	27
12	Primary cutaneous and subcutaneous Ewing sarcoma. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1555-1561.	1.5	25
13	Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma. <i>BMJ Open</i> , 2019, 9, e025877.	1.9	23
14	A multicentric randomized phase II clinical trial evaluating high-dose thiotepa as adjuvant treatment to standard chemotherapy in patients with resectable relapsed osteosarcoma. <i>European Journal of Cancer</i> , 2020, 125, 58-68.	2.8	23
15	Bone Sarcomas: From Biology to Targeted Therapies. <i>Sarcoma</i> , 2012, 2012, 1-18.	1.3	22
16	Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoposide (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to <math>\leq 25</math> years with relapsed/refractory osteosarcoma (OS).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11527-11527.	1.6	22
17	Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer Research. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 1034-1043.	2.1	18
18	Ewing's Sarcoma of the Head and Neck: Margins are not just for surgeons. <i>Cancer Medicine</i> , 2018, 7, 5879-5888.	2.8	17

#	ARTICLE	IF	CITATIONS
19	MT2A is an early predictive biomarker of response to chemotherapy and a potential therapeutic target in osteosarcoma. <i>Scientific Reports</i> , 2019, 9, 12301.	3.3	14
20	Recent advances in understanding osteosarcoma and emerging therapies. <i>Faculty Reviews</i> , 2020, 9, 18.	3.9	14
21	Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis. <i>Cancer Research</i> , 2022, 82, 974-985.	0.9	14
22	Methotrexateâ€“Etoposideâ€“Ifosfamide Compared with Doxorubicinâ€“Cisplatinâ€“Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18â€“25 Years. <i>Journal of Adolescent and Young Adult Oncology</i> , 2020, 9, 172-182.	1.3	13
23	Synergistic Anti-Tumor Effect of Simvastatin Combined to Chemotherapy in Osteosarcoma. <i>Cancers</i> , 2021, 13, 5869.	3.7	13
24	Establishment and characterization of <i>in vivo</i> orthotopic bioluminescent xenograft models from human osteosarcoma cell lines in Swiss nude and NSG mice. <i>Cancer Medicine</i> , 2018, 7, 665-676.	2.8	12
25	Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment?. <i>Cancers</i> , 2021, 13, 423.	3.7	12
26	High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group. <i>Sarcoma</i> , 2014, 2014, 1-7.	1.3	11
27	Successive Osteosarcoma Relapses after the First Line O2006/Sarcome-09 Trial: What Can We Learn for Further Phase-II Trials?. <i>Cancers</i> , 2021, 13, 1683.	3.7	11
28	In-Vitro and In-Vivo Establishment and Characterization of Bioluminescent Orthotopic Chemotherapy-Resistant Human Osteosarcoma Models in NSG Mice. <i>Cancers</i> , 2019, 11, 997.	3.7	10
29	Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas. <i>European Journal of Cancer</i> , 2022, 173, 71-90.	2.8	9
30	Management of sarcomas in children, adolescents and adults: Interactions in two different age groups under the umbrellas of GSF-GETO and SFCE, with the support of the NETSARC+ network. <i>Bulletin Du Cancer</i> , 2021, 108, 163-176.	1.6	7
31	Evidence of increasing mortality with longer time to diagnosis of cancer: Is there a paediatric exception?. <i>European Journal of Cancer</i> , 2014, 50, 864-866.	2.8	5
32	Together Intra-Tumor Hypoxia and Macrophagic Immunity Are Driven Worst Outcome in Pediatric High-Grade Osteosarcomas. <i>Cancers</i> , 2022, 14, 1482.	3.7	5
33	Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma. <i>Clinical Sarcoma Research</i> , 2018, 8, .	2.3	3
34	Head and neck Ewing sarcoma: French surgical practice analysis pleads for surgery centralization. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2022, 50, 439-448.	1.7	3
35	OLIE, ITCC-082: a Phase II trial of lenvatinib plus ifosfamide and etoposide in relapsed/refractory osteosarcoma. <i>Future Oncology</i> , 2021, 17, 4249-4261.	2.4	2
36	Prognostic impact of pulmonary nodules diagnosed at initial presentation in patients with osteosarcoma. <i>Pediatric Blood and Cancer</i> , 2022, , e29725.	1.5	1